Skip to main content

CARD, Lineagen Offering ASD Test

NEW YORK (GenomeWeb News) – The Center for Autism and Related Disorders and molecular diagnostics firm Lineagen today announced a partnership to offer the FirstStep genetic test to patients.

Lineagen's whole-genome genetic test for autism spectrum disorders will be integrated with pre- and post-genetic counseling services and personalized reporting and will be available to patients in CARD's Skills program. The program is designed to meet clinical guidelines recommending chromosomal microarray analysis as a first-line genetic test to evaluate individuals with ASD.

"Recent scientific literature and clinical guidelines have recommended genetic testing and counseling for children with ASDs," CARD Founder and Executive Director Doreen Granpeesheh said in a statement. "In selecting a partner in this area, CARD chose Lineagen's FirstStepDx because it includes the most advanced technology complemented with the personal service similar to that provided by CARD to each patient and family."

Lineagen is based in Salt Lake City. Earlier this year it began incorporating Affymetrix's GeneChip technology into its genetic evaluation service for patients with developmental delay, intellectual disability, and autism spectrum disorders.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.